Jed Brody, Head of Americas Healthcare Banking

Barclays appoints Jed Brody as Head of Americas Healthcare Banking

Barclays today announces the appointment of Jed Brody as a Managing Director and Head of Americas Healthcare Banking. Mr. Brody will be based in New York, and report to Rick Landgarten, Global Head of Healthcare and Real Estate Investment Banking.

Mr. Brody rejoins Barclays from Leerink Partners (formerly SVB), where he was a Senior Managing Director. Prior to joining SVB in 2021, Mr. Brody was at Barclays. During his career Mr. Brody has worked on a number of notable transactions including the sale of LHC Group to UnitedHealth for $5.4bn, CVS Health’s $69bn acquisition of Aetna, ICU Medical’s $2.35bn acquisition of Smiths Medical, the recapitalization of RxBenefits involving Great Hill Partners and Advent International, and Centene’s $17.3bn acquisition of WellCare. Mr. Brody has over 20 years of experience in the industry, and before joining Barclays began his career with Lehman Brothers.

“We are delighted to welcome Jed back to Barclays. His deep relationships in the Healthcare industry, together with his extensive experience in working on complex transactions, will be of tremendous value to our existing and future clients,” said Rick Landgarten.

“Jed is a proven leader, and he will play a key role in strengthening the connectivity between our teams and our clients as we continue to invest in our Healthcare coverage,” added Taylor Wright, Global Co-Head of Investment Banking at Barclays.

Other recent hires and appointments in Barclays’ Healthcare Investment Banking group include Jon Swope being appointed to the Healthcare Information Technology Banking team, and Maneet Singh and Evan Matlin being named Co-Heads of M&A Healthcare in the US. In addition, Jim Birchenough was appointed as Chairman of Global Healthcare Investment Banking and Co-Head of Global Biopharma Investment Banking, Alexis de Rosnay as Co-Head of Global Biopharma Investment Banking and Chairman of Global Healthcare Investment Banking, and Jeff Ammerman as Global Head of Specialty Pharmaceuticals Investment Banking.